Home » Stocks » AngioDynamics

AngioDynamics, Inc. (ANGO)

Stock Price: $11.03 USD 0.12 (1.05%)
Updated Oct 23, 2020 3:52 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 418.43M
Revenue (ttm) 268.33M
Net Income (ttm) -169.78M
Shares Out 37.95M
EPS (ttm) -4.46
PE Ratio n/a
Forward PE 370.37
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $11.03
Previous Close $10.91
Change ($) 0.12
Change (%) 1.05%
Day's Open 11.00
Day's Range 10.72 - 11.16
Day's Volume 109,915
52-Week Range 7.48 - 17.24

More Stats

Market Cap 418.43M
Enterprise Value 410.50M
Earnings Date (est) Jan 7, 2021
Ex-Dividend Date n/a
Shares Outstanding 37.95M
Float 36.69M
EPS (basic) -4.46
EPS (diluted) -4.46
FCF / Share -0.55
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 876,620
Short Ratio 2.58
Short % of Float 2.39%
Beta 0.50
PE Ratio n/a
Forward PE 370.37
P/FCF Ratio n/a
PS Ratio 1.56
PB Ratio 0.91
Revenue 268.33M
Operating Income -183.13M
Net Income -169.78M
Free Cash Flow -21.11M
Net Cash 7.93M
Net Cash / Share 0.21
Gross Margin 56.00%
Operating Margin -68.25%
Profit Margin -63.30%
FCF Margin -7.87%
ROA -1.84%
ROE -31.76%
ROIC -151.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 0
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$14.00*
Low
14.0
Current: $11.03
High
14.0
Target: 14.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue264271262270354357354342222216
Revenue Growth-2.39%3.43%-3.01%-23.77%-0.74%0.6%3.66%54.07%2.86%-
Gross Profit150156144144174176180169125126
Operating Income-179-16.17-13.92-26.441.97-11.558.587.87-3.9111.96
Net Income-16761.3416.345.01-43.59-3.392.35-1.21-5.188.12
Shares Outstanding37.9637.4937.0836.6236.1635.6835.1434.8225.3824.87
Earnings Per Share-4.391.640.440.14-1.21-0.090.07-0.03-0.200.32
EPS Growth-272.73%214.29%-------
Operating Cash Flow-14.5537.4441.2955.7545.2225.6924.6826.6511.6033.87
Capital Expenditures-7.24-3.12-2.39-3.00-2.33-11.38-11.17-12.12-2.49-2.96
Free Cash Flow-21.7934.3238.9052.7442.8914.3013.5114.539.1130.91
Cash & Equivalents54.4422875.4148.7633.9920.0817.9123.9637.58132
Total Debt40.0013291.6296.321211381431431506.55
Net Cash / Debt14.4495.73-16.21-47.56-86.56-118-125-119-112125
Assets594836705708726773799791722437
Liabilities13922216319321922826226519831.78
Book Value455615543515507545537526524406
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AngioDynamics, Inc.
Country United States
Employees 800
CEO James Christopher Clemmer

Stock Information

Ticker Symbol ANGO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: ANGO
IPO Date May 27, 2004

Description

AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.